Abstract

Review Article

Impact of alloimmunization on transfusion-dependent patients

Surapon Tangvarasittichai*

Published: 16 November, 2017 | Volume 1 - Issue 1 | Pages: 070-082

Red blood cell (RBC) alloimmunization can be a life-threatening complication for patients with thalassemia major and sickle cell disease (SCD) who must receive chronic therapeutic transfusions. Chronic transfusions can lead to erythrocyte alloimmunization, patients continue to develop alloantibodies due to the transference of the immunogenic antigens on the donor RBCs. Many complications are possible. Difficulty in finding compatible match units for the patients can cause transfusion delays delayed, or present alternative risks to the patients from delayed hemolytic transfusion reactions. This review discusses the possible mechanisms, risk factors associated with alloimmunization formation and the hemolytic transfusion reactions and also describe the guideline for transfusion management of these patients, including opportunities and emerging approaches for minimizing this life-threatening complication.

Read Full Article HTML DOI: 10.29328/journal.aac.1001009 Cite this Article Read Full Article PDF

Keywords:

Alloimmunization; RBC transfusion; RBC antigen; Hemolytic transfusion reaction; β-thalassemia syndrome; Sickle cell disease

References

  1. Kruatrachue M, Sirisinha S, Pacharee P, Chandarayingyong D, Wasi P. An association between thalassemia and autoimmune haemolytic anaemia (AIHA). Scand J Haematol. 1980; 25: 259-263. Ref.: https://goo.gl/cmb2Jd
  2. Argiolu F, Diana G, Arnone M, Batzella MG, Piras P, et al. High-dose intravenous immunoglobulin in the management of autoimmune hemolytic anemia complicating thalassemia major. Acta Haematol. 1990; 83: 65-68. Ref.: https://goo.gl/tNQZDG
  3. Cianciulli P, Sorrentino F, Morino L, Massa A, Sergiacomi GL, et al. Radiotherapy combined with erythropoietin for the treatment of extramedullary hematopoiesis in an alloimmunized patient with thalassemia intermedia. Ann Hematol. 1996; 73: 379-381. Ref.: https://goo.gl/84UXXV
  4. Tangvarasittichai S. Thalassemia syndromes. In: Ikehara K. eds. Advances in the study of genetic disorders. InTech. Janeza Trdine 9, 51000 Rijeka, Croatia. 2011; 101-148.
  5. Galanello R, Sanna S, Perseu L, Sollaino MC, Satta S, et al. Amelioration of Sardinian beta0 thalassemia by genetic modifiers. Blood. 2009; 114: 3935-3937. Ref.: https://goo.gl/6Yprtc
  6. Rachmilewitz EA, Giardina PJ. How I treat thalassemia. Blood. 2011; 118: 3479-3788. Ref.: https://goo.gl/upxZhy
  7. Muncie HL Jr, Campbell J. Alpha and beta thalassemia. Am Fam Physician. 2009; 80: 339-344. Ref.: https://goo.gl/U53rf5
  8. Rivella S. b-Thalassemias: paradigmatic diseases for scientific discoveries and development of innovative therapies. Haematologica. 2015; 100: 418-430. Ref.: https://goo.gl/ypkaSd
  9. Galanello R, Origa R. Beta-thalassemia. Orphanet J Rare Dis. 2010; 5: 11. Ref.: https://goo.gl/AXyJyD
  10. Ameen R, Al-Shemmari S, Al-Humood S, Chowdhury RI, Al-Eyaadi O, et al. RBC alloimmunization and autoimmunization among transfusion dependent Arab Thalassemia patients. Transfusion. 2003; 43: 1604-1610. Ref.: https://goo.gl/NVMY5o
  11. Jansuwan S, Tangvarasittichai O, Tangvarasittichai S. Alloimmunization to Red Cells and the Association of alloantibodies formation with splenectomy among transfusion-dependent b-thalassemia major/HbE patients. Ind J Clin Biochem. 2015; 30: 198-203. Ref.: https://goo.gl/uavmMo
  12. Frenette PS, Atweh GF. Sickle cell disease: old discoveries, new concepts, and future promise. J Clin Invest. 2007; 117: 850-858. Ref.: https://goo.gl/Yz7php
  13. Walter PB, Harmatz P, Vichinsky E. Iron metabolism and iron chelation in sickle cell disease. Acta Haematol. 2009; 122: 174-183. Ref.: https://goo.gl/NZnxiA
  14. Yazdanbakhsh K, Ware RE, Noizat-Pirenne F. Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management. Blood. 2012; 120: 528-537. Ref.: https://goo.gl/xi9nqr
  15. Prigent A, Maillard N, Absi L, Aloui C, Cognasse F, et al. From donor to recipient: Current questions relating to humoral alloimmunization. Antibodies.2014; 3: 130-152. Ref.: https://goo.gl/kFA3f9
  16. Shamsian BS, Taghi AM, Shamshiri AR, Alavi S, Khojasteh, O. Frequency of red cell alloimmunization in patients with β-major thalassemia in an Iranian referral hospital. Iran J Pediatr. 2008; 18: 149-153. Ref.: https://goo.gl/vTTXAGf
  17. Singer ST, Wu V, Mignacca R, Kuypers FA, Morel P, et al. Alloimmunization and erythrocyte autoimmunization in transfusion-dependent thalassemia patients of predominantly Asian descent. Blood. 2000; 96: 3369-3373. Ref.: https://goo.gl/f7vpEF
  18. 2017; Ref.: http://www.isbtweb.org
  19. Ballif BA, Helias V, Peyrard T, Menanteau C, Saison C, et al. Disruption of SMIM1 causes the Vel-blood type. EMBO Mol Med. 2013; 5: 751-761. Ref.: https://goo.gl/wpkZ7Y
  20. Storry JR, Jöud M, Christophersen MK, Thuresson B, Åkerström B, et al. Homozygosity for a null allele of SMIM1 defines the Vel-negative blood group phenotype. Nat Genet. 2013; 45: 537-541. Ref.: https://goo.gl/X7MtPD
  21. Cvejic A, Haer-Wigman L, Stephens JC, Kostadima M,  Smethurst PA, et al. SMIM1 underlies the Vel blood group and influences red blood cell traits. Nat Genet. 2013; 45: 542-545. Ref.: https://goo.gl/3JKJFY
  22. De La Vega Elena CD, Nogués N, Fernández Montoya A, Chialina S, Blanzaco PD, et al. Human platelet-specific antigens frequencies in the Argentinean population. Transfus Med. 2008; 18: 83-90. Ref.: https://goo.gl/WJXh8k
  23. Curtis BR, McFarland JG. Human platelet antigens - 2013. Vox Sang. 2014; 106: 93-102. Ref.: https://goo.gl/AU1etB
  24. Metcalfe P, Watkins NA, Ouwehand WH, Kaplan C, Newman P, et al. Nomenclature of human platelet antigens. Vox Sang. 2003; 85: 240-245. Ref.: https://goo.gl/CzpXDw
  25. Zimring JC, Welniak L, Semple JW, Ness PM, Slichter SJ, et al. Current problems and future directions of transfusion-induced alloimmunization: summary of an NHLBI working group. Transfusion. 2011; 51: 435-441. Ref.: https://goo.gl/c6QMCS
  26. Brouk H, Halle L, Bertrand G, Neche FZ, Ouelaa H, et al. Human platelet antigen allele frequencies in different Algerian populations. Tissue Antigens. 2010; 75: 673-678. Ref.: https://goo.gl/T2Pu8W
  27. Pavenski K, Freedman J, Semple JW. HLA alloimmunization against platelet transfusions: pathophysiology, significance, prevention and management. Tissue Antigens. 2012; 79: 237-245. Ref.: https://goo.gl/BxLxiC
  28. van de Watering L, Hermans J, Witvliet M, Versteegh M, Brand A. HLA and RBC immunization after filtered and buffy coat-depleted blood transfusion in cardiac surgery: a randomized controlled trial. Transfusion. 2003; 43: 765-771. Ref.: https://goo.gl/rtgXS3
  29. de La Vega Elena CD, Nogués N, Fernández Montoya A, Oyonarte S, Solis E, et al. HNA-1a, HNA-1b and HNA-1c gene frequencies in Argentineans. Tissue Antigens. 2008; 71: 475-477. Ref.: https://goo.gl/jfi2Ay
  30. Xia W, Bayat B, Sachs U, Chen Y, Shao Y, et al. The frequencies of human neutrophil alloantigens in the Chinese Han population of Guangzhou. Transfusion. 2011; 51: 1271-1277. Ref.: https://goo.gl/gFoSw6
  31. Bux J. Human neutrophil alloantigens. Vox Sang. 2008; 94: 277-285. Ref.: https://goo.gl/EkwJ3b
  32. Bux J, Behrens G, Jaeger G, Welte K. Diagnosis and clinical course of autoimmune neutropenia in infancy: analysis of 240 cases. Blood. 1998; 91: 181-186. Ref.: https://goo.gl/9mV6ov
  33. Looney MR, Gropper MA, Matthay MA. Transfusion-related acute lung injury: A review. Chest. 2004; 126: 249-258. Ref.: https://goo.gl/7LPjK1
  34. Garratty G. Advances in red blood cell immunology 1960 to 2009. Transfusion. 2010; 50: 526-535. Ref.: https://goo.gl/xMfBnq
  35. The Trial to Reduce Alloimmunization to Platelets Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med. 1997; 337: 1861-1869. Ref.: https://goo.gl/Jafw9j
  36. Mincheff M. Changes in donor leukocytes during blood storage. Implications on post-transfusion immunomodulation and transfusion-associated GVHD. Vox Sang. 1998; 74: 189-200. Ref.: https://goo.gl/mFGGNj
  37. Zimring JC, Stowell SR, Johnsen JM, Hendrickson JE. Effects of genetic, epigenetic, and environmental factors on alloimmunization to transfused antigens: Current paradigms and future considerations. Transfus Clin Biol. 2012; 19: 125-131. Ref.: https://goo.gl/Qy1tza
  38. Zalpuri S, Middelburg RA, Schonewille H, de Vooght KM, le Cessie S, et al. Intensive red blood cell transfusions and risk of alloimmunization. Transfusion. 2014; 54: 278-284. Ref.: https://goo.gl/j6RdFm
  39. Bauer MP, Wiersum-Osselton J, Schipperus M, Vandenbroucke JP, Briët E. Clinical predictors of alloimmunization after red blood cell transfusion. Transfusion. 2007; 47: 2066-2071. Ref.: https://goo.gl/rPR8Av
  40. Giblett ER. A critique of the theoretical hazard of inter vs intra-racial transfusion. Transfusion. 1961; 1: 233-238. Ref.: https://goo.gl/Kum3U3
  41. Tormey CA, Stack G. Immunogenicity of blood group antigens: a mathematical model corrected for antibody evanescence with exclu­sion of naturally occurring and pregnancy-related antibodies. Blood. 2009; 114: 4279-4282. Ref.: https://goo.gl/52qhTs
  42. Alves VM, Martins PRJ, Soares S, Araújo G, Schmidt LC, et al. Alloimmunization screening after transfusion of red blood cells in a prospective study. Rev Bras Hematol Hemoter. 2012; 34: 206. Ref.: https://goo.gl/tR7mbC
  43. Santos FW, Magalhaes SM, Mota RM, Pitombeira MH. Post transfusion red cells alloimmunization in patients with acute disorders and medical emergencies. Rev Bras Hematol Hemother. 2007; 29: 369. Ref.: https://goo.gl/1K3Vvo
  44. Verduin EP, Brand A, Schonewille H. Is female sex a risk factor for red blood cell alloimmunization after transfusion? A systematic review. Transfus Med Rev. 2012; 26: 342-353. Ref.: https://goo.gl/9b3zqm
  45. Lomas-Francis C. Testing for rare blood donors by DNA analysis. ISBT Sci Series. 2006; 1: 213-219. Ref.: https://goo.gl/6WjNLQ
  46. Daniels G. The molecular genetics of blood group polymorphism.Transpl Immunol. 2005; 14: 143-153. Ref.: https://goo.gl/hm7KND
  47. Lasalle-Williams M, Nuss R, Le T, Hassell K, Murphy JR, et al. Extended red blood cell antigen matching for transfusions in sickle cell disease: a review of a 14-year experience from a single center. Transfusion. 2011; 51: 1732-1739. Ref.: https://goo.gl/S9aEsp
  48. Spanos TH, Karageorga M, Ladis V, Peristeri J, Hatziliami A, Kattamis C. Red cell alloantibodies in patients with thalassemia. Vox Sang. 1990; 58: 50-55. Ref.: https://goo.gl/oVmskT
  49. Hendrickson JE, Desmarets M, Deshpande SS, Chadwick TE, Hillyer CD, et al. Recipient inflammation affects the frequency and magnitude of immunization to transfused red blood cells. Transfusion. 2006; 46: 1526-1536. Ref.: https://goo.gl/o6oFp1
  50. Cognasse F, Boussoulade F, Chavarin P, Acquart S, Fabrigli P, et al. Release of potential immunomodulatory factors during platelet storage. Transfusion. 2006; 46: 1184-1189. Ref.: https://goo.gl/WJ6W8X
  51. Hod EA, Spitalnik SL. Stored red blood cell transfusions: Iron, inflammation, immunity, and infection. Transfus Clin Biol. 2012; 19: 84-89. Ref.: https://goo.gl/fS2q4X
  52. Seftel MD, Growe GH, Petraszko T, Benny WB, Le A, et al. Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness. Blood. 2004; 103: 333-339. Ref.: https://goo.gl/V62djQ
  53. Slichter SJ. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N. Engl. J. Med. 1997; 337: 1861-1869. Ref.: https://goo.gl/thsUDF
  54. Marschner S, Fast LD, Baldwin WM 3rd, Slichter SJ, Goodrich RP. White blood cell inactivation after treatment with riboflavin and ultraviolet light. Transfusion. 2010; 50: 2489-2498. Ref.: https://goo.gl/LFqnC9
  55. Bilgin YM, van de Watering LM, Brand A. Clinical effects of leucoreduction of blood transfusions. Neth J Med. 2011; 69: 441-450. Ref.: https://goo.gl/c32HML
  56. Hendrickson JE, Chadwick TE, Roback JD, Hillyer CD, Zimring JC. Inflammation enhances consumption and presentation of transfused RBC antigens by dendritic cells. Blood. 2007; 110: 2736-2743. Ref.: https://goo.gl/uwQnUK
  57. Smith NH, Hod EA, Spitalnik SL, Zimring JC, Hendrickson JE. Transfusion in the absence of inflammation induces antigen-specific tolerance to murine RBCs. Blood. 2012; 119: 1566-1569. Ref.: https://goo.gl/hDr95M
  58. Zimring JC, Stowell SR, Johnsen JM, Hendrickson JE. Effects of genetic, epigenetic, and environmental factors on alloimmunization to transfused antigens: Current paradigms and future considerations. Transfus Clin Biol. 2012; 19: 125-131. Ref.: https://goo.gl/wznBkj
  59. Papay P, Hackner K, Vogelsang H, Novacek G, Primas C, et al. High risk of transfusion-induced alloimmunization of patients with inflammatory bowel disease. Am J Med. 2012; 125: 717. Ref.: https://goo.gl/eWqwjJ
  60. Yazer MH, Triulzi DJ, Shaz B, Kraus T, Zimring JC. Does a febrile reaction to platelets predispose recipients to red blood cell alloimmunization? Transfusion. 2009; 49: 1070-1075. Ref.: https://goo.gl/ttnZzx
  61. Tatari-Calderone Z, Luban NLC, Vukmanovic S. Genetics of Transfusion Recipient Alloimmunization: Can Clues from Susceptibility to Autoimmunity Pave the Way?. Transfus Med Hemother. 2014; 41: 436-445. Ref.: https://goo.gl/YHJtNz
  62. Aygun B, Padmanabhan S, Paley C, Chandrasekaran V. Clinical significance of RBC alloantibodies and autoantibodies in sickle cell patients who received transfusions. Transfusion. 2002; 42: 37-43. Ref.: https://goo.gl/bgLJGk
  63. Bao W, Yu J, Heck S, Yazdanbakhsh K. Regulatory T-cell status in red cell alloimmunized responder and nonresponder mice. Blood. 2009; 113: 5624-5627. Ref.: https://goo.gl/6d4qoQ
  64. Yu J, Heck S, Yazdanbakhsh K. Prevention of red cell alloimmunization by CD25 regulatory T cells in mouse models. Am. J. Hematol. 2007; 82: 691-696. Ref.: https://goo.gl/59Euzw
  65. Bao W, Zhong H, Manwani D, Vasovic L, Uehlinger J, Lee MT, et al. Regulatory B-cell compartment in transfused alloimmunized and nonalloimmunized patients with sickle cell disease. Am J Hematol. 2013; 88: 736-740. Ref.: https://goo.gl/DCikdP
  66. Bao W, Zhong H, Li X, Lee MT, Schwartz J, et al. Immune regulation in chronically transfused alloantibody responder and nonresponder patients with sickle cell disease and beta-thalassemia major. Am J Hematol. 2011; 86: 1001-1006. Ref.: https://goo.gl/dfa6Q1
  67. Aslam R, Hu Y, Gebremeskel S, Segel GB, Speck ER, et al. Thymic retention of CD 4+CD 25+FoxP 3+ T regulatory cells is associated with their peripheral deficiency and thrombocytopenia in a murine model of immune thrombocytopenia. Blood. 2012; 120: 2127.
  68. Castellino SM, Combs MR, Zimmerman SA, Issitt PD, Ware RE. Erythrocyte autoantibodies in paediatric patients with sickle cell disease receiving transfusion therapy: Frequency, characteristics and significance. Br. J. Haematol. 1999; 104: 189-194. Ref.: https://goo.gl/XPe1fk
  69. Strobel E. Chronic hemolytic transfusion reactions. Transfus Med Hemother. 2008; 35: 346-353. Ref.: https://goo.gl/GHcrtb
  70. Chapman JF, Elliott C, Knowles SM, Milkins CE, Poole GD, Transfusion Task Force members. Guidelines for compatibility procedures in blood transfusion laboratories. Working Party of the British Committee for Standards in Haematology Blood Transfusion Task Force. Transfus Med. 2004; 14: 59.
  71. Silvy M, Tournamille C, Babinet J, Pakdaman S, Cohen S, et al. Red blood cell immunization in sickle cell disease: evidence of a large responder group and a low rate of anti-Rh linked to partial Rh phenotype. Haematologica. 2014; 99: 115-117. Ref.: https://goo.gl/24wcMN
  72. Cappellini MD, Cohen A, Porter J, Taher A, Viprakasit V, editors. Guidelines for the management of TransfusionDependent Thalassaemia (TDT). 3rd ed. Nicosia (CY): Thalassaemia International Federation; 2014.
  73. Michail-Merianou V, Pamphili-Panousopoulou L, Piperi-LowesL, Pelegrinis E, Karaklis A. Alloimmunization to red cellantigens in thalassemia: comparative study of usual versusbetter-match transfusion programmes. Vox Sang.1987; 52: 95-98. Ref.: https://goo.gl/wGV2JM
  74. Cazzola M, Borgna-Pignatti C, Locatelli F, Ponchio L, Beguin Y, et al. A moderate transfusion regimen may reduce iron loading in beta-thalassemia major without producing excessive expansion of erythropoiesis. Transfusion.1997; 37:135-140. Ref.: https://goo.gl/NJSUdc
  75. Cazzola M, De Stefano P, Ponchio L, Locatelli F, Beguin Y, Dessi C, et al. Relationship between transfusion regimen and suppression of erythropoiesis in beta-thalassaemia major. Br J Haematol. 1995; 89: 473-478. Ref.: https://goo.gl/oSy4PD
  76. Noizat-Pirenne F, Bachir D, Chadebech P, Michel M, Plonquet A, et al. Rituximab for prevention of delayed hemolytic transfusion reaction in sickle cell disease. Haematologica. 2007; 92: 132-135. Ref.: https://goo.gl/J183wj
  77. Veldhuisen B, van der Schoot CE, de Haas M. Blood group genotyping: from patient to high through put donor screening. Vox Sang. 2009; 97: 198-206. Ref.: https://goo.gl/kysVnY

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?